Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

P21 regulatory status

Current status of P21 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of P21?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
P21 is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing.
WADA
WADA prohibited
Access path
  1. Not legally available for human use in the United States: no FDA approved product and no federal basis to compound it from bulk.
  2. Not an FDA approved drug and not compoundable under 503A or 503B.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Full P21 page: evidence, dosing in the literature, and sources

How has the status of P21 changed over time?

No dated regulatory event has been recorded for P21. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for P21 and the source of each dated event.

  1. [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
  2. [2]FDA: Compounding and the FDA, questions and answersFDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026